Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=323 An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…
N/A N=14 First Episode Schizophrenia and Cannabis-Related Disorder Study
Cannabis-Related Disorder · Substance-Related Disorders · Schizophrenia
Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants
Phase 4 N=299 An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24 — 72.4; -6.9 Units on a scale
N/A N=404 An Integrated Program for the Treatment of First Episode of Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145
Phase 3 N=386 To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia
Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses
Phase 4 N=133 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale
Phase 4 N=31 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
Schizophrenia · Dual Diagnosis · Schizoaffective Disorder
Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088
Phase 4 N=491 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
Schizophrenia
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…
N/A N=63 Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia
Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale
N/A N=20 Clinical Trial of Dipyridamole in Schizophrenia
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale
Phase 3 N=403 A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 — 77.18; 58.46; 63.33; -26.29 unit on a scale
Phase 1 N=22 A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
Schizophrenia
Primary: Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA. — -0.0007; -0.0008; -0.0006; -0.0008 Kicer — p=0.0072
Phase 4 N=60 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
Phase 3 N=244 A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Schizophrenia · Schizoaffective Disorder
Primary: Time to Relapse of Psychotic Symptoms During 6 Weeks — 23.8; 16.9; 17.3 days
Phase 4 N=42 Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
Smoking Cessation · Schizophrenia
Primary: Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM) — 11.5; 12.3; 12.0; 7.8 ppm
Phase 3 N=1,117 Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 85.19; 65.45; -26.60; -20.52 units on a scale
N/A N=10 An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia
Schizophrenia
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia — 95; 75 scores on a scale
N/A N=176 Brief Group Psychoeducation for Schizophrenia
Schizophrenia
Primary: Number of Participants With Relapse — 22; 23 Participants — p=0.59
N/A N=88 Cognitive-Behavioral Therapy in Veterans With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30
Phase 4 N=45 Intranasal Insulin Treatment in Patients With Schizophrenia
Schizophrenia
Primary: Cognitive Function- Digit Span Total — 13.3; 14.1 Items correct
Phase 4 N=67 High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
Schizophrenia
Primary: Change in Positive Symptoms of Schizophrenia — 22.6; 24.2 units on a scale
Phase 3 N=228 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935
Phase 2 N=41 Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Verbal Short Term Memory — 43.7; 37.9; 43.6; 40.8 t-score — p=0.90
N/A N=100 Psychosis: Early Detection, Intervention and Prevention
Prodromal Schizophrenia · Psychotic Disorders · Severe Bipolar Disorder With Psychotic Features
Primary: Onset of Psychosis — 10; 14 percentage of sample converting
Phase 4 N=39 Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
Schizophrenia · Schizoaffective Disorder · Substance Use Disorders
Primary: Timeline Follow Back (TLFB) — -1.765; -.532 score on a scale
Phase 4 N=60 Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
Schizophrenia · Schizoaffective Disorder
Primary: Change in Cognition and Psychopathology Disorders as Measured on the MATRICS Consensus Cognitive Battery (MCCB) — 14.1; 14.3 units on a scale
Phase 2 N=61 A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
Schizophrenia
Primary: Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study — 59 participants
Phase 3 N=294 An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
Schizophrenia
Primary: Number of Participants With Treatment Response Based on Total PANSS Scale Score — 195 Participants
N/A N=538 Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes
Schizophrenia
Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001